ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alto Neuroscience Inc (ANRO) does not present a compelling buy opportunity for a beginner, long-term investor at this time. Despite some positive technical indicators, the lack of strong financial performance, hedge fund selling, and mixed analyst sentiment suggest caution. The stock's recent failure in a key clinical trial and weak financials further diminish its attractiveness.
The technical indicators show a bullish trend with MACD positively expanding, RSI at 75.553 in the neutral zone, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the stock is nearing resistance levels (R1: 26.575) and has limited upside potential in the short term.
Analysts highlight potential in Alto's pipeline, particularly in depression-related treatments (ALTO-207, ALTO-300, ALTO-100). The company has a $275M cash reserve to support its operations and upcoming catalysts.
The recent failure of the ALTO-101 Phase 2 trial for schizophrenia has led to significant price target reductions and market skepticism. Hedge funds are selling heavily, with a 159.20% increase in selling activity over the last quarter. The financials remain weak, with negative net income and declining EPS.
In 2025/Q4, revenue remained at 0 with no growth, net income improved slightly to -$16.18M (up 6.45% YoY), but EPS dropped to -0.47 (down -17.54% YoY). Gross margin remains at 0, indicating no revenue generation.
Analysts have mixed views. H.C. Wainwright maintains a Buy rating with a $50 price target, citing a catalyst-rich 2026. However, other firms like Baird and JonesResearch have lowered price targets due to the recent trial failure. Wedbush downgraded the stock to Neutral with a $21 price target, removing ALTO-101 from their valuation.
